Corticosteroid Eyedrops Market Report 2026

Corticosteroid Eyedrops Market Overview

• Corticosteroid Eyedrops market size has reached to $10 billion in 2025 • Expected to grow to $13.69 billion in 2030 at a compound annual growth rate (CAGR) of 6.4% • Growth Driver: Rising Prevalence Of Eye Diseases Driving The Growth Of The Market Due To Increasing Digital Eye Strain And Sight Loss Trends • Market Trend: FDA Approval Of Clobetasol Propionate Marks Major Advancement In Corticosteroid Eyedrops Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Corticosteroid Eyedrops Market?

Corticosteroid eyedrops refer to specialized prescription medications that contain corticosteroids, which are powerful anti-inflammatory agents designed to reduce swelling, redness, and irritation in the eyes. These eyedrops are commonly used to treat various eye conditions such as uveitis, allergic conjunctivitis, and inflammation following eye surgeries or injuries, helping to prevent tissue damage and promote faster healing. The main types of products in corticosteroid eyedrops are topical corticosteroid eyedrops, systemic corticosteroid eyedrops, and combination therapy eyedrops. Topical corticosteroid eyedrops are liquid medications applied directly to the surface of the eye to reduce inflammation. They are available in various delivery devices such as dropper bottles, spray formulations, ointments and gels, and punctal plugs, and they are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and others. Their applications cover both adults and children, serving a wide range of end users such as hospitals, specialty clinics, community pharmacies, and online pharmacies.

What Is The Corticosteroid Eyedrops Market Growth Forecast?

The corticosteroid eyedrops market size is expected to see strong growth in the next few years. It will grow to $13.69 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to development of advanced combination therapy eyedrops, rise in pediatric ophthalmology treatments, growth of online pharmacy distribution, increasing adoption of patient-centric delivery devices, regulatory approvals for novel corticosteroid formulations. Major trends in the forecast period include rising prevalence of eye disorders requiring anti-inflammatory therapy, growing preference for combination therapy eyedrops, increased adoption of pediatric-friendly formulations, expansion of online and retail pharmacy channels, focus on improving drug stability and patient compliance.

What Is The Driver Of The Corticosteroid Eyedrops Market?

The rising prevalence of eye diseases is expected to propel the growth of the corticosteroid eyedrops market going forward. Eye diseases refer to conditions that affect the health and function of the eyes, potentially leading to vision problems or even blindness if not properly managed. The prevalence of eye diseases is rising due to increasing screen time, which leads to digital eye strain and contributes to conditions such as dry eye and blurred vision. Corticosteroid eyedrops are commonly used to treat eye diseases by reducing inflammation and relieving symptoms such as redness, swelling, and discomfort. For instance, in May 2024, according to the report published by the Joint Strategic Needs Assessment, a UK-based community health center, approximately 2 million people in the UK currently live with some degree of sight loss, a number projected to increase to 2.7 million by 2030. Therefore, the rising prevalence of eye diseases is driving the growth of the corticosteroid eyedrops industry.

Key Players In The Global Corticosteroid Eyedrops Market

Major companies operating in the corticosteroid eyedrops market are Pfizer Inc., AbbVie Inc., Novartis AG, Alcon Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Santen Pharmaceutical Co. Ltd., Lupin Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Sunways Pvt. Ltd., FDC Limited, Eurocrit Labs International Pvt. Ltd., Entod Pharmaceuticals Pvt. Ltd., Akorn Pharmaceuticals Inc., Kala Pharmaceuticals Inc.

Global Corticosteroid Eyedrops Market Trends and Insights

Major companies operating in the corticosteroid eyedrops market are focusing on obtaining regulatory approvals to expand their product portfolios and enhance market access. Regulatory approvals refer to the official authorization granted by health authorities, ensuring that corticosteroid eyedrops meet required safety, efficacy, and quality standards before being marketed and prescribed to patients. For instance, in March 2024, Formosa Pharmaceuticals Inc., a Taiwan-based pharmaceutical company, and AimMax Therapeutics, a US-based pharmaceutical company, received FDA approval for clobetasol propionate ophthalmic suspension 0.05% (APP13007) for the treatment of postoperative inflammation and pain following ocular surgery. Developed using Formosa’s APNT nanoparticle technology, this corticosteroid formulation allows for effective drug delivery with a simple twice-daily dosing for 14 days without tapering. Clinical trials demonstrated its strong anti-inflammatory effects, making it a promising addition to corticosteroid treatment options for managing inflammation and pain after eye surgery. As the first ophthalmic corticosteroid containing clobetasol and the first new steroid approved in this category in over 15 years, it represents a significant advancement in ocular corticosteroid therapy.

What Are Latest Mergers And Acquisitions In The Corticosteroid Eyedrops Market?

In June 2025, Harrow Inc., a US-based eyecare pharmaceutical company, acquired the exclusive U.S. commercial rights to Byqovi (clobetasol propionate ophthalmic suspension) 0.05% from Formosa Pharmaceuticals Inc. for an undisclosed amount. With this acquisition, Harrow aims to expand its surgical care ophthalmology portfolio by adding a newly FDA approved high potency steroid for post operative inflammation and pain. Formosa Pharmaceuticals, Inc. is a Taiwan based biotechnology company focused on ophthalmology and oncology using proprietary nanoparticle formulation technology.

What Defines the Corticosteroid Eyedrops Market?

The corticosteroid eyedrops market consists of sales of low-potency corticosteroid eyedrops, ointments, subconjunctival injections, antibiotic formulations, and periocular injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Corticosteroid Eyedrops Market Report 2026?

The corticosteroid eyedrops market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the corticosteroid eyedrops industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.